BMO Capital reiterates Acadia Pharmaceuticals stock rating despite trial failure

Acadia Pharmaceuticals (ACAD) shares are under pressure after its Phase 3 COMPASS trial for Prader-Willi Syndrome treatment ACP-101 failed to meet its primary endpoint, leading to the program's discontinuation, a setback BMO Capital deemed "meaningful." Concurrently, Soleno Therapeutics has seen increased investor interest following Acadia's failure, despite concerns over a patient death associated with its Vykat XR; multiple analysts, including TD Cowen, Stifel, and Baird, have maintained positive ratings, largely dismissing the death as unrelated to the medication and highlighting successful launch performance.

Analysis

Acadia Pharmaceuticals (ACAD) has experienced a significant research and development setback with the failure of its Phase 3 COMPASS trial for ACP-101 in treating Prader-Willi Syndrome. The drug failed to demonstrate any statistically significant benefit over placebo on both primary and key secondary endpoints, prompting management to discontinue the program entirely, a move described by BMO Capital as a 'meaningful step back'. Despite this failure and an anticipated share price decline, BMO maintained its Outperform rating and $28.00 price target, suggesting the trial's success may have been discounted or that their valuation is predicated on other assets. In direct contrast, Soleno Therapeutics (SLNO) has benefited from Acadia's failure, with its stock gaining traction as a key competitor is removed from the Prader-Willi Syndrome market. This positive momentum for Soleno persists despite a notable safety concern—a patient death reported in the FDA's Adverse Event Reporting System (FAERS) linked to its drug, Vykat XR. However, a strong analyst consensus from TD Cowen, Stifel, and Baird has defended the drug's safety profile, with price targets ranging from $118 to $121, attributing the death to the patient's pre-existing conditions and highlighting that the commercial launch of Vykat XR is already exceeding expectations.

Key Decisions for Investors

• Investors in Acadia Pharmaceuticals should assess the impact of the ACP-101 trial failure on the company's long-term R&D valuation, noting that BMO Capital's maintained Outperform rating implies value exists in the remaining pipeline or commercial portfolio.
• Soleno Therapeutics presents a cleared competitive path for its Prader-Willi Syndrome treatment, but investors must monitor for any further adverse event reports or regulatory scrutiny regarding Vykat XR, which could challenge the current positive analyst outlook.
• The situation presents a clear catalyst-driven pairs trade consideration: long Soleno Therapeutics (SLNO) to capture the enhanced market position, and short Acadia Pharmaceuticals (ACAD) based on its significant clinical setback.